Literature DB >> 7527993

[Cultural and linguistic validation, in Spanish, of the International Prostatic Symptoms Scale (I-PSS)].

R Vela Navarrete1, J M Martín Moreno, F J Calahorra, J Damián Moreno, A Hernández Coronado, P Boyle.   

Abstract

Formal presentation of the cultural and linguistic validation, in Spanish, of the International Prostatic Symptoms Scale (I-PSS). The process for the official translation into Spanish of the questionnaire on prostatic symptomatology and quality of live derived from urinary symptoms, has followed a methodology common to several countries (UK, Italy, Norway, The Netherlands and Spain) which consisted in: translation into Spanish of the original American-English version published by the WHO in 1992, by two independent bilingual urologists; re-translation into English, checking any conceptual and semantic changes that had caused difficulties in the process of translation/re-translation; final choice of the text by an International Committee based both on the data provided by the above process and the experience of the Central Committee accrued over their relationships with the various National Committees. The resulting text was applied to 33 patients with prostate disease and 12 controls, individually recording any difficulty of interpretation and choice of answer observed for each of the questions. The final text herewith presented constitutes the official reference for the Spanish translation of the International Prostatic Symptoms Scale (I-PSS) which should be used for future symptomatic evaluations. The purpose of this cultural and linguistic validation is to secure that the application of these scales provides comparable and consistent numerical results in those countries where the translation has not been officially validated.

Entities:  

Mesh:

Year:  1994        PMID: 7527993

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  3 in total

1.  Linguistic adaptation and validation of the Spanish version of the Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM).

Authors:  Carlos Llorente; Miguel Ruiz; Javier Rejas Gutiérrez; Manuel Esteban; Fernando Villasante; Asha Hareendran
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

2.  [Referral criteria for benign prostatic hyperplasia in primary care].

Authors:  José María Molero; David Pérez Morales; Francisco José Brenes Bermúdez; Esperanza Naval Pulido; Antonio Fernández-Pro; Juan Antonio Martín; Jesús Castiñeiras Fernández; José Manuel Cozar Olmo
Journal:  Aten Primaria       Date:  2009-11-14       Impact factor: 1.137

3.  Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.

Authors:  N Martell; M Luque
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jul-Aug       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.